Recent Advances in diabetic nephropathy

Marshall, S. M.
November 2004
Postgraduate Medical Journal;Nov2004, Vol. 80 Issue 949, p624
Academic Journal
Diabetic nephropathy is the leading cause of end stage renal disease worldwide and is associated with increased cardiovascular risk. The earliest clinical manifestation is of microalbuminuria. Tight blood glucose and blood pressure control reduce the risk of microalbuminuria. Once microalbuminuria is present, the rate of progression to end stage renal disease and of cardiovascular disease can be delayed by aggressive management of blood pressure, glucose, and lipids. Inhibition of the renin-angiotensin system is important to reduce intraglomerular pressure but other classes of antihypertensive agent may also be needed to gain adequate control of systemic blood pressure. Such measures can at least half the rate of progression of nephropathy and cardiovascular disease.


Related Articles

  • Arterial Stiffness Is Inversely Related to Plasma Adiponectin Levels in Young Normotensive Patients With Type 1 Diabetes. Tsiakou, Afroditi; Liatis, Stavros; Alexiadou, Kleopatra; Diakoumopoulou, Evanthia; Makrilakis, Konstantinos; Tentolouris, Nicholas; Kyriaki, Despoina; Katsilambros, Nicholas // Diabetes Care;Mar2013, Vol. 36 Issue 3, p734 

    OBJECTIVE -- This study investigated the association between arterial stiffness and plasma adiponectin in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS -- Participants were normotensive patients with type 1 diabetes who were up to age 40 years. Subjects on statins with macrovascular...

  • Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Gross, Jorge L.; De Azevedo, Mirela J.; Silveiro, Sandra P.; Canani, Luís Henrique; Caramori, Maria Luiza; Zelmanovitz, Themis // Diabetes Care;Jan2005, Vol. 28 Issue 1, p164 

    Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ∼40% of type 1 and type 2 diabetic patients. It increases the risk of death, mainly from cardiovascular causes, and is defined by increased urinary albumin excretion (UAE)...

  • The detection and measurement of microalbuminuria: a challenge for clinical chemistry. Busby, Douglas E.; Atkins, Robert C. // MLO: Medical Laboratory Observer;Feb2005, Vol. 37 Issue 2, p8 

    Focuses on the need for the early identification of microalbuminaria (MA) as a risk factor in diabetic nephropathy and cardiovascular disease (CVD). Percentage of the overall prevalence of MA in persons with a diagnosis of diabetes; Establishment of MA as strong, independent risk factor for CVD...

  • Outcome variables in the assessment of progression of diabetic kidney disease. Viberti, GianCarlo // Kidney International Supplement;Feb1994, Issue 45, pS-121 

    Focuses on the outcome variables in the assessment of progression of diabetic kidney disease. Use of surrogate endpoints in the evaluation of the progression of nephropathy; Correlation between glomerular structure and renal function in diabetes; Criteria for ascribing causality to the...

  • Renal Disease in Cardiovascular Disorders: An Underrecognized Problem. Baumelou, Alain; Bruckert, Eric; Bagnis, Corinne; Deray, Gilbert // American Journal of Nephrology;Mar/Apr2005, Vol. 25 Issue 2, p95 

    Chronic renal disease is generally appreciated as a major and rapidly growing health problem. In the United States alone, as many as 19.5 million people may have markers of early renal disease, and more than 660,000 people are expected to require renal replacement therapy by the year 2010. By...

  • Effect of Telmisartan on Renal Outcomes. Mann, Johannes F. E.; Schmieder, Roland E.; Dyal, Leanne; McQueen, Matthew J.; Schumacher, Helmut; Pogue, Janice; Xingyu Wang; Probstfield, Jeffrey L.; Avezum, Alvaro; Cardona-Munoz, Ernesto; Dagenais, Gilles R.; Diaz, Rafael; Fodor, George; Maillon, Jean M.; Rydén, Lars; Yu, Cheuk M.; Teo, Koon K.; Yusuf, Salim // Annals of Internal Medicine;7/7/2009, Vol. 151 Issue 1, p1 

    Background: Angiotensin-receptor blockers (ARBs) blunt progression of advanced diabetic nephropathy, but their long-term renal effects in other patients are not clear. Objective: To examine the long-term renal effects of telmisartan versus placebo in adults at high vascular risk. Design:...

  • Enhanced posttransplant management of patients with diabetes improves patient outcomes. Keddis, Mira T; El Ters, Mireille; Rodrigo, Emilio; Dean, Patrick; Wohlfahrtova, Mariana; Kudva, Yogish C; Lorenz, Elizabeth C; Cosio, Fernando G // Kidney International;Sep2014, Vol. 86 Issue 3, p610 

    The survival of patients with diabetes mellitus in the general population has improved in recent years. Here we assessed whether similar trends have occurred in 1688 kidney recipients, including 413 with diabetes prior to transplant between 1996 and 2007. Compared to patients without diabetes,...

  • Early detection and prevention of diabetic nephropathy: A challenge calling for mandatory action for Mexico and the developing world. Correa-Rotter, Ricardo; González-Michaca, Luis // Kidney International Supplement;Sep2005, Issue 98, pS69 

    Early detection and prevention of diabetic nephropathy: A challenge calling for mandatory action for Mexico and the developing world. During the last decades, developing countries have experienced an epidemiologic transition characterized by a reduction of infectious diseases and an increase of...

  • The earlier the referral of diabetic nephropathy patients to a diabetic-renal clinic, the slower the renal decline.  // Kidney;Sep/Oct2002, Vol. 11 Issue 5, p205 

    Presents a summary of the study 'Diabetic Nephropathy: How Effective is Treatment in Clinical Practice?,' by N. Joss, K.R. Paterson, C.J. Deighan, et al, published in a 2002 issue of 'Quarterly Journal of Medicine.'


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics